Epidemiology of invasive group a streptococcal disease in Alaska, 2001 to 2013

Journal of Clinical Microbiology

Volumn 54, Issue 1, 2016, Pages 134-141

  Rudolph, Karen ^a   Bruce, Michael G ^a   Bruden, Dana ^a   Zulz, Tammy ^a   Reasonover, Alisa ^a   Hurlburt, Debby ^a   Hennessy, Thomas ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFOTAXIME; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; PENICILLIN DERIVATIVE; TETRACYCLINE; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; CARRIER PROTEIN; OUTER MEMBRANE PROTEIN; STREPTOCOCCAL M PROTEIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CHILD; CONTROLLED STUDY; EPIDEMIC; FEMALE; GROUP A STREPTOCOCCAL INFECTION; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; POPULATION RESEARCH; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; STREPTOCOCCUS GROUP A; UNITED STATES; ALASKA; ARCTIC; CLASSIFICATION; DRUG EFFECTS; GENETICS; GENOTYPE; INFANT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; NEWBORN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALASKA; ANTI-BACTERIAL AGENTS; ANTIGENS, BACTERIAL; ARCTIC REGIONS; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84954322914     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02122-15     Document Type: Review

References (46)

1. Cunningham MW. 2000. Pathogenesis of group A streptococci. Clin Micro-biol Rev 13:470-491. http://dx.doi.org/10.1128/CMR.13.3.470-511.2000.
2. Carapetis JR, Steer AC, Mulholland EK, Weber M. 2005. The global burden of group A streptococcal diseases. Lancet Infect Dis 5:685-694. http://dx.doi.org/10.1016/S1473-3099(05)70267-X.
3. Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. 2009. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet 9:611-616. http://dx.doi.org/10.1016/S1473-3099(09)70178-1.
4. Carapetis JR, Robins-Browne R, Martin D, Shelby-James T, Hogg G. 1995. Increasing severity of invasive group A streptococcal disease in Australia: clinical and molecular epidemiological features and identification of a new virulent M-nontypeable clone. Clin Infect Dis 21:1220-1227. http://dx.doi.org/10.1093/clinids/21.5.1220.
5. Colman G, Tanna A, Efstratiou A, Gaworzewska ET. 1993. The sero-types of Streptococcus pyogenes present in Britain during 1980-1990 and their association with disease. J Med Microbiol 39:165-178. http://dx.doi.org/10.1099/00222615-39-3-165.
6. Holm SE, Norrby A, Bergholm AM, Norgren M. 1992. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 166:31-37. http://dx.doi.org/10.1093/infdis/166.1.31.
7. Martin J, Murchan S, O'Flanagan D, Fitzpatrick F. 2011. Invasive group A streptococcal disease in Ireland, 2004 to 2010. Eurosurveillance 16:1-7.
8. O'Brien KL, Beall B, Barrett NL, Cieslak PR, Reingold A, Farley MM, Danila R, Zell ER, Facklam R, Schwartz B, Schuchat A, Active Bacterial Core Surveillance/Emerging Infections Program Network. 2002. Epidemiology of invasive group A Streptococcus disease in the United States, 1995-1999. Clin Infect Dis 35:268-276. http://dx.doi.org/10.1086/341409.
9. O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, Albanese BA, Farley MM, Barrett NL, Spina NL, Beall B, Harrison LH, Reingold A, Van Beneden C, Active Bacterial Core Surveillance Team. 2007. The epidemiology of invasive group A strep-tococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 45:853-862. http://dx.doi.org/10.1086/521264.
10. Athey TBT, Teatero S, Li A, Marchand-Austin A, Beall B, Fittipaldi N. 2014. Deriving groupA streptococcus typing information from short-read whole-genome sequencing data. J Clin Microbiol 52:1871-1876. http://dx.doi.org/10.1128/JCM.00029-14.
11. Beall B, Facklam R, Thompson T. 1996. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J Clin Microbiol 34:953-958.
12. Creti R, Imperi M, Baldassarri L, Pataracchia M, Recchia S, Alfarone G, Orefici G. 2007. emm types, virulence factors, and antibiotic resistance of invasive Streptococcus pyogenes isolates from Italy: what has changed in 11 years? J Clin Microbiol 45:2249-2256. http://dx.doi.org/10.1128/JCM.00513-07.
13. Darenberg J, Luca-Harari B, Jasir A, Sandgren A, Pettersson H, Schalén C, Norgren M, Romanus V, Norrby-Teglund A, Normark BH. 2007. Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis 45:450-458. http://dx.doi.org/10.1086/519936.
14. Ekelund K, Darenberg J, Norrby-Teglund A, Hoffmann S, Bang D, Skinhøj P, Konradsen H. 2005. Variations in emm type among group A streptococcal isolates causing invasive and noninvasive infections in a nationwide study. J Clin Microbiol 43:3101-3109. http://dx.doi.org/10.1128/JCM.43.7.3101-3109.2005.
15. Imöhl M, Reinert RR, Ocklenburg C, van der Linden M. 2010. Epidemiology of invasive Streptococcus pyogenes disease in Germany during 2003-2007. FEMS Immunol Med Microbiol 58:389-396. http://dx.doi.org/10.1111/j.1574-695X.2010.00652.x.
16. Krucsó B, Gacs M, Libisch B, Hunyadi ZV, Molnár K, Füzi M, Pászti J. 2007. Molecular characterization of invasive Streptococcus pyogenes isolates from Hungary obtainedin 2004 and 2005. EurJ Clin Microbiol Infect Dis 26:807-811. http://dx.doi.org/10.1007/s10096-007-0359-4.
17. Meisal R, Høiby EA, Aaberge IS, Caugant DA. 2008. Sequence type and emm type diversity in Streptococcus pyogenes isolates causing invasive disease in Norway between 1988 and 2003. J Clin Microbiol 46:2102-2105. http://dx.doi.org/10.1128/JCM.00363-08.
18. Montes M, Ardanuy C, Tamayo E, Domènech A, Liñares J, Pérez-Trallero E. 2011. Epidemiology and molecular analysis of Streptococcus pyogenes isolates causing invasive disease in Spain (1998-2009): comparison with non-invasive isolates. Eur J Clin Microbiol Infect Dis 30:1295-1302. http://dx.doi.org/10.1007/s10096-011-1226-x.
19. O'Grady KF, Kelpie L, Andrews RM, Curtis N, Nolan TM, Selvaraj G, Passmore JW, Oppedisano F, Carnie JA, Carapetis JR. 2007. The epidemiology of invasive group A streptococcal disease in Victoria, Australia. Med J Australia 186:565-569.
20. Siljander T, Lyytikäinen O, Vähäkuopus S, Snellman M, Jalava J, Vuopio J. 2010. Epidemiology, outcome and emm types of invasive group A streptococcal infections in Finland. Eur J Clin Microbiol Infect Dis 29:1229-1235. http://dx.doi.org/10.1007/s10096-010-0989-9.
21. Stathi A, Papaparaskevas J, Zachariadou L, Pangalis A, Legakis NJ, Tseleni-Kotsovili A, Tassios PT, the Hellenic Strep-EURO Study Group. 2008. Prevalence of emm types 1 and 12 from invasive Streptococcus pyogenes disease in Greece-results of enhanced surveillance. Clin Microbiol Infect 14:808-812. http://dx.doi.org/10.1111/j.1469-0691.2008.02032.x.
22. Szczypa K, Sadowy E, Isdebski R, Strakove L, Hryniewicz W. 2006. Group A streptococci from invasive-disease episodes in Poland are remarkably divergent at the molecular level. J Clin Microbiol 44:3975-3979. http://dx.doi.org/10.1128/JCM.01163-06.
23. Baird RW, Bronze MS, Kraus W, Hill HR, Veasey LG, Dale JB. 1991. Epitopes of group A streptococcal M protein shared with antigens of articular cartilage and synovium. J Immunol 146:132-137.
24. Bronze MS, Dale JB. 1993. Epitopes of streptococcal M proteins that evoke antibodies that cross-react with human brain. J Immunol 151: 2820-2828.
25. Dale JB, Penfound T, Chiang EY, Long V, Shulman ST, Beall B. 2005. Multivalent group A streptococcal vaccine elicits bactericidal antibodies against variant M subtypes. Clin Diagn Lab Immunol 12:833-836.
26. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. 2002. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Im-mun 70:2171-2177. http://dx.doi.org/10.1128/IAI.70.4.2171-2177.2002.
27. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB. 2004. Safety and immunogenicity of a recombi-nant multivalent group A streptococcal vaccine in healthy adults: phase 1 trial. JAMA 292:709-715. http://dx.doi.org/10.1001/jama.292.6.709.
28. Olive C, Hsien K, Horváth A, Clair T, Yarwood P, Toth I, Good MF. 2005. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Vaccine 23:2298-2303. http://dx.doi.org/10.1016/j.vaccine.2005.01.041.
29. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB. 2005. Safety and immunogenicity of 26-valent group A Streptococcus vaccine in health adult volunteers. Clin Infect Dis 41:1114-1122. http://dx.doi.org/10.1086/444458.
30. Dale JB, Penfound TA, Chiang EY, William WJ. 2011. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 29:8175-8178. http://dx.doi.org/10.1016/j.vaccine.2011.09.005.
31. Dale JB, Penfound TA, Tamboura B, Sow SO, Nataro JP, Tapia M, Kotloff KL. 2013. Potential coverage of a multivalent M protein-based group A streptococcal vaccine. Vaccine 31:1576-1581. http://dx.doi.org/10.1016/j.vaccine.2013.01.019.
32. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement M100-S21, vol. 31. Clinical and Laboratory Stantards Institute, Wayne, PA.
33. State of Alaska Department of Labor and Workforce Development. 2014. http://www.labor.alaska.gov/research/pop/popest.htm. Accessed 11 February 2015.
34. Simpson EH. 1949. Mesurement of diversity. Nature 163:688. http://dx.doi.org/10.1038/163688a0.
35. Magurran AE. 2004. Measuring biological diversity. Blackwell Publishing, Oxford, United Kingdom.
36. Vlaminckx BJM, van Pelt W, Schouls LM, van Silfhout A, Mascini EM, Elzenaar CP, Fernandes T, Bosman A, Schellekens JFP. 2005. Long-term surveillance of invasive group A streptococcal disease in The Netherlands, 1994-2003. Clin Microbiol Infect 11:226-231. http://dx.doi.org/10.1111/j.1469-0691.2004.01068.x.
37. Stockmann C, Ampofo K, Hersh AL, Blaschke AJ, Kendall BA, Kor-genski K, Daly J, Hill HR, Byington CL, Pavia AT. 2012. Evolving epidemiologic characteristics of invasive group a streptococcal disease in Utah, 2002-2010. Clin Infect Dis 55:479-487. http://dx.doi.org/10.1093/cid/cis422.
38. Norton R, Smith RV, Wood N, Siegbrecht E, Ross A, Ketheesan N. 2004. Invasive group A streptococcal disease in North Queensland (1996-2001). Indian J Med Res 119(Suppl):148-151.
39. Safar A, Lennon D, Stewart J, Trenholme A, Drinkovic D, Peat B, Taylor S, Read K, Roberts S, Voss L. 2011. Invasive group A streptococ-cal infection and vaccine implications, Auckland, New Zealand. Emerg Infect Dis 17:983-989. http://dx.doi.org/10.3201/eid/1706.100804.
40. Steer AC, Jenney A, Kado J, Good MF, Batzloff M, Waqatakirewz L, Mullholland EK, Carapetis JR. 2009. Prospective surveillance of invasive groupA streptococcal diseaseinFiji, 2005-2007. Emerg Infect Dis 15:216-222. http://dx.doi.org/10.3201/eid15/2.080558.
41. Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, Vuopio-Varkila J, Bouvet A, Creti R, Ekelund K, Koliou M, Reinert RR, Stathi A, Strakova L, Ungureanu V, Schalén C, the Strep-EURO Study Group, Jasir A. 2008. Epidemiology of severe Streptcococcus pyogenes disease in Europe. J Clin Microbiol 46:2359-2367. http://dx.doi.org/10.1128/JCM.00422-08.
42. Luca-Harari B, Ekelund K, van der Linden M, Staum-Kaltoft M, Ham-merum A, Jasir A. 2008. Clinical and epidemiological aspects of invasive Streptococcus pyogenesinfections inDenmark during 2003 and 2004.J Clin Microbiol 46:79-86. http://dx.doi.org/10.1128/JCM.01626-07.
43. Ato M, Ikebe T, Kawabata H, Takemori T, Watanabe H. 2008. Incompetence of neutrophils to invasive group A streptococcus is attributed to induction of plural virulence factors by dysfunction of a regulator. PLoS One 3:e3455. http://dx.doi.org/10.1371/journal.pone.0003455.
44. Ikebe T, Endoh M, Watanabe H. 2005. Increased expression of the ska gene in emm49-genotyped Streptococcus pyogenes strains isolates from patients with severe invasive streptococcal infections. Jpn J Infect Dis 58:272-275.
45. Sanderson-Smith M, De Oliveira DMP, Guglielmini J, McMillan DJ, Vu T, Holien JK, Henningham A, Steer AC, Bessen DE, Dale JB, Curtis N, Beall BW, Walker MJ, Parker MW, Carapetis JR, Van Melderen L, Sriprakash KS, Smeesters PR, M Protein Study Group. 2014. A system atic and functional classification of Streptococcus pyogenes that serves as a new tool for molecular typing and vaccine development. J Infect Dis 210: 1325-1338. http://dx.doi.org/10.1093/infdis/jiu260.
46. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Miller AL, Rice CL, Doern CD, Reid SD, Doern GV. 2005. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 41:599-608. http://dx.doi.org/10.1086/432473.